Merck's KEYTRUDA Combo Wins and Pipeline Shuffle Might Change The Case For Investing In Merck (MRK) [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
assets across kidney, ovarian and bladder cancers, HIV and RSV, alongside a reorganization of its human health business and new oncology leadership appointments. Together, these updates highlight Merck's push to turn KEYTRUDA-centered regimens and newer drugs like WELIREG, LENVIMA, ENFLONSIA and DOR/ISL into a broader oncology and infectious disease franchise as it prepares for KEYTRUDA's eventual loss of exclusivity. We'll now examine how the adjuvant renal cell carcinoma win for KEYTRUDA plus WELIREG may influence Merck's pipeline-driven investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Merck Investment Narrative Recap To own Merck today, you need to believe its broad pipeline and newer launches can steadily reduce dependence on KEYTRUDA, especially as loss of exclusivity looms as the defining risk. The new renal, ovarian an
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Assessing Merck (MRK) Valuation As Recent Share Price Strength Meets Conflicting Fair Value Views [Yahoo! Finance]Yahoo! Finance
- ???????:???????????2035????411.8?????????? ? ???????????????? [CNET News]CNET News
- Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead? [Yahoo! Finance]Yahoo! Finance
- Big Pharma's next entrant could come from China [Yahoo! Finance]Yahoo! Finance
- Merck Keytruda Combos Strengthen Oncology Platform And Raise Patent Questions [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- 2/13/26 - Form 144/A
- MRK's page on the SEC website